@article{RN6178,
   author = {Zong, H. and Verhaak, R. G. and Canoll, P.},
   title = {The cellular origin for malignant glioma and prospects for clinical advancements},
   journal = {Expert Rev Mol Diagn},
   volume = {12},
   number = {4},
   pages = {383-94},
   note = {1744-8352
Zong, Hui
Verhaak, Roel G W
Canoll, Peter
R01NS066955/NS/NINDS NIH HHS/United States
R01CA136495/CA/NCI NIH HHS/United States
R01 CA136495/CA/NCI NIH HHS/United States
U24CA143883/CA/NCI NIH HHS/United States
R01 NS066955/NS/NINDS NIH HHS/United States
U24 CA143883/CA/NCI NIH HHS/United States
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
England
2012/05/24
Expert Rev Mol Diagn. 2012 May;12(4):383-94. doi: 10.1586/erm.12.30.},
   abstract = {Glioma remains incurable despite great advancements in medicine. Targeting the cell of origin for gliomas could bring great hope for patients. However, as a collection of diverse diseases, each subtype of glioma could derive from a distinct cell of origin. To resolve such a complex problem, one must use multiple research approaches to gain deep insights. Here we review current evidence regarding the cell of origin from clinical observations, whole-genome molecular pathology and glioma animal models. We conclude that neural stem cells, glial progenitors (including oligodendrocyte progenitor cells) and astrocytes could all serve as cells of origin for gliomas, and that cells incurring initial mutations (cells of mutation) might not transform, while their progeny cells could instead transform and act as cells of origin. Further studies with multidisciplinary approaches are needed to link each subtype to a particular cell of origin, and to develop effective therapies that target the signaling network within these cells.},
   keywords = {Animals
Brain Neoplasms/genetics/*pathology
Disease Models, Animal
Glioma/genetics/*pathology
Humans
Mutation},
   ISSN = {1473-7159 (Print)
1473-7159},
   DOI = {10.1586/erm.12.30},
   year = {2012},
   type = {Journal Article}
}

{"_id":"taHm8FmpaE3Aewjfq","bibbaseid":"zong-verhaak-canoll-thecellularoriginformalignantgliomaandprospectsforclinicaladvancements-2012","authorIDs":["5dce3b23dcea22df0100007c","5dec52fce16431f2010000c9","5dec5944e16431f2010000fa","5e0a5e7ace3ebce40100010e","5e2ff5be5bfc8ede0100003b","c8zrScQz6casKGL4t"],"author_short":["Zong, H.","Verhaak, R. G.","Canoll, P."],"bibdata":{"bibtype":"article","type":"Journal Article","author":[{"propositions":[],"lastnames":["Zong"],"firstnames":["H."],"suffixes":[]},{"propositions":[],"lastnames":["Verhaak"],"firstnames":["R.","G."],"suffixes":[]},{"propositions":[],"lastnames":["Canoll"],"firstnames":["P."],"suffixes":[]}],"title":"The cellular origin for malignant glioma and prospects for clinical advancements","journal":"Expert Rev Mol Diagn","volume":"12","number":"4","pages":"383-94","note":"1744-8352 Zong, Hui Verhaak, Roel G W Canoll, Peter R01NS066955/NS/NINDS NIH HHS/United States R01CA136495/CA/NCI NIH HHS/United States R01 CA136495/CA/NCI NIH HHS/United States U24CA143883/CA/NCI NIH HHS/United States R01 NS066955/NS/NINDS NIH HHS/United States U24 CA143883/CA/NCI NIH HHS/United States Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review England 2012/05/24 Expert Rev Mol Diagn. 2012 May;12(4):383-94. doi: 10.1586/erm.12.30.","abstract":"Glioma remains incurable despite great advancements in medicine. Targeting the cell of origin for gliomas could bring great hope for patients. However, as a collection of diverse diseases, each subtype of glioma could derive from a distinct cell of origin. To resolve such a complex problem, one must use multiple research approaches to gain deep insights. Here we review current evidence regarding the cell of origin from clinical observations, whole-genome molecular pathology and glioma animal models. We conclude that neural stem cells, glial progenitors (including oligodendrocyte progenitor cells) and astrocytes could all serve as cells of origin for gliomas, and that cells incurring initial mutations (cells of mutation) might not transform, while their progeny cells could instead transform and act as cells of origin. Further studies with multidisciplinary approaches are needed to link each subtype to a particular cell of origin, and to develop effective therapies that target the signaling network within these cells.","keywords":"Animals Brain Neoplasms/genetics/*pathology Disease Models, Animal Glioma/genetics/*pathology Humans Mutation","issn":"1473-7159 (Print) 1473-7159","doi":"10.1586/erm.12.30","year":"2012","bibtex":"@article{RN6178,\n author = {Zong, H. and Verhaak, R. G. and Canoll, P.},\n title = {The cellular origin for malignant glioma and prospects for clinical advancements},\n journal = {Expert Rev Mol Diagn},\n volume = {12},\n number = {4},\n pages = {383-94},\n note = {1744-8352\nZong, Hui\nVerhaak, Roel G W\nCanoll, Peter\nR01NS066955/NS/NINDS NIH HHS/United States\nR01CA136495/CA/NCI NIH HHS/United States\nR01 CA136495/CA/NCI NIH HHS/United States\nU24CA143883/CA/NCI NIH HHS/United States\nR01 NS066955/NS/NINDS NIH HHS/United States\nU24 CA143883/CA/NCI NIH HHS/United States\nJournal Article\nResearch Support, N.I.H., Extramural\nResearch Support, Non-U.S. Gov't\nReview\nEngland\n2012/05/24\nExpert Rev Mol Diagn. 2012 May;12(4):383-94. doi: 10.1586/erm.12.30.},\n abstract = {Glioma remains incurable despite great advancements in medicine. Targeting the cell of origin for gliomas could bring great hope for patients. However, as a collection of diverse diseases, each subtype of glioma could derive from a distinct cell of origin. To resolve such a complex problem, one must use multiple research approaches to gain deep insights. Here we review current evidence regarding the cell of origin from clinical observations, whole-genome molecular pathology and glioma animal models. We conclude that neural stem cells, glial progenitors (including oligodendrocyte progenitor cells) and astrocytes could all serve as cells of origin for gliomas, and that cells incurring initial mutations (cells of mutation) might not transform, while their progeny cells could instead transform and act as cells of origin. Further studies with multidisciplinary approaches are needed to link each subtype to a particular cell of origin, and to develop effective therapies that target the signaling network within these cells.},\n keywords = {Animals\nBrain Neoplasms/genetics/*pathology\nDisease Models, Animal\nGlioma/genetics/*pathology\nHumans\nMutation},\n ISSN = {1473-7159 (Print)\n1473-7159},\n DOI = {10.1586/erm.12.30},\n year = {2012},\n type = {Journal Article}\n}\n\n","author_short":["Zong, H.","Verhaak, R. G.","Canoll, P."],"key":"RN6178","id":"RN6178","bibbaseid":"zong-verhaak-canoll-thecellularoriginformalignantgliomaandprospectsforclinicaladvancements-2012","role":"author","urls":{},"keyword":["Animals Brain Neoplasms/genetics/*pathology Disease Models","Animal Glioma/genetics/*pathology Humans Mutation"],"metadata":{"authorlinks":{"verhaak, r":"https://verhaaklab.com/publications/bib/"}},"downloads":0},"bibtype":"article","biburl":"https://verhaaklab.com/files/verhaak.bib","creationDate":"2019-11-15T05:44:04.167Z","downloads":0,"keywords":["animals brain neoplasms/genetics/*pathology disease models","animal glioma/genetics/*pathology humans mutation"],"search_terms":["cellular","origin","malignant","glioma","prospects","clinical","advancements","zong","verhaak","canoll"],"title":"The cellular origin for malignant glioma and prospects for clinical advancements","year":2012,"dataSources":["iFXeF2qjAL2y5TeTz"]}